|
1）Hsu M, Sasaki M, Igarashi S, et al. KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic choloangiocarcinomas. Cancer. 2013; 119: 1669-74
|
|
|
|
2）Matthaei H, Wu J, Molin MD, et al. GNAS codon 201 mutations are uncommon in intraductal papillary neoplasms of the bile duct. HPB. 2012; 14: 677-83
|
|
|
|
|
|
3）Tsai JH, Yuan RH, Chen YL, et al. GNAS is frequently mutated in a specific subgroup of intraductal papillary neoplasms of the bile duct. Am J Surg Pathol. 2013; 37: 1862-70
|
|
|
|
|
|
4）Sasaki M, Matsubara T, Nitta T, et al. GNAS and KRAS mutations are common in intraductal papillary neoplasms of the bile duct. PLoS One. 2013; 8: e81706
|
|
|
|
|
|
5）Schlitter AM, Born D, Bettstetter M, et al. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways. Mod Pathol. 2014; 27: 73-86
|
|
|
|
|
|
6）Jain K, Mohapatra T, Das P, et al. Sequential occurrence of preneoplastic lesions and accumulation of loss of heterozygosity in patients with gallbladder stones suggest causal association with gallbladder cancer. Ann Surg. 2014; 260: 1073-80
|
|
|
|
|
|
7）Chan-on W, Nairismagi ML, Ong CK, et al. Exon sequencing identifies distinct mutational patterns in liver fluke-related and non-infection –related bile duct cancers. Nat Genet. 2013; 45: 1474-78
|
|
|
|
|
|
8）Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013; 45: 1470-3
|
|
|
|
|
|
9）Wang P, Dong Q, Zhang C, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene. 2013; 32: 3091-100
|
|
|
|
|
|
10）Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 2008; 48: 308-21
|
|
|
|
|
|
11）Zheng T, Hong X, Wang J, et al. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma. Hepatology. 2014; 59: 935-46
|
|
|
|
|
|
12）Leelawat K, Thongtawee T, Narong S, et al. Strong expression of CD133 is associated with increased cholangiocarcinoma progression. World J Gastroenterol. 2011; 17: 1192-8
|
|
|
|
|
|
13）Tmai K, Nakamura M, Mizuma M, et al. Suppressive expression of CD274 increases tumorigenesis and cancer stem cell phenotypes in cholangiocarcinoma. Cancer Sci. 2014; 105: 667-74
|
|
|
|
|
14）Peng F, Jiang J, Yu Y, et al. Direct targeting of SUZ12/ROCK2 by miR-200b/c inhibits cholangiocarcinoma tumorigenesis and metastasis. Br J Cancer. 2013; 109: 3092-104
|
|
|
|
|
|
15）Chang Y, Liu C, Yang J, et al. miR-20a triggers metastasis of gallbladder carcinoma. J Hepatol. 2013; 59: 518-27
|
|
|
|
|